Literature DB >> 21682831

Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease.

Mami Mori1, Hideki Fujii, Tomohiro Ogawa, Sawako Kobayashi, Shuji Iwai, Hiroyasu Morikawa, Masaru Enomoto, Akihiro Tamori, Ayumi Sawada, Setsuko Takeda, Norifumi Kawada.   

Abstract

AIM: Transient elastography is known as a rapid, objective, and highly reliable technique for staging hepatic fibrosis caused by hepatitis C virus infection; however, the relationship between degree of fibrosis and the collagen deposition or the accumulation of myofibroblasts in non-alcoholic fatty liver disease (NAFLD) remains to be further elucidated.
METHODS: The subjects were 36 patients with NAFLD who received liver biopsy and liver stiffness measurement using transient elastography. Their clinical data and laboratory values were collected. Morphometric analyses of liver fibrosis indicated by collagen deposition and the relative numbers of myofibroblasts were performed.
RESULTS: Liver stiffness measured by transient elastography correlated with histopathological fibrosis staging of NAFLD determined by Brunt's scoring system (P = 0.000149). The fibrosis staging correlated with the ratios of the Sirius red-positive area (P = 0.000032) and α-smooth muscle actin-positive area (P = 0.000898). Finally, liver stiffness significantly correlated with the ratios of the Sirius red-positive area (r = 0.390, P = 0.0184) and α-smooth muscle actin-positive area (r = 0.333, P = 0.0471).
CONCLUSIONS: Liver stiffness measurement by transient elastography is valuable for evaluating fibrotic progression in NAFLD.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 21682831     DOI: 10.1111/j.1872-034X.2011.00842.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Authors:  Sila Cocciolillo; Giustino Parruti; Leonardo Marzio
Journal:  World J Hepatol       Date:  2014-07-27

Review 2.  Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B.

Authors:  Masaru Enomoto; Hiroyasu Morikawa; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver.

Authors:  Hiroyuki Motoyama; Tohru Komiya; Le Thi Thanh Thuy; Akihiro Tamori; Masaru Enomoto; Hiroyasu Morikawa; Shuji Iwai; Sawako Uchida-Kobayashi; Hideki Fujii; Atsushi Hagihara; Etsushi Kawamura; Yoshiki Murakami; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Lab Invest       Date:  2013-12-02       Impact factor: 5.662

4.  Gestation Food Restriction and Refeeding Compensate Maternal Energy Status and Alleviate Metabolic Consequences in Juvenile Offspring in a Rabbit Model.

Authors:  Rosa M Garcia-Garcia; María Arias-Alvarez; Pilar Millan; María Rodriguez Francisco; Ana Sanchez Rodriguez; Pedro L Lorenzo; Pilar G Rebollar
Journal:  Nutrients       Date:  2021-01-22       Impact factor: 5.717

5.  Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?

Authors:  Giovanni Tarantino
Journal:  Hepat Mon       Date:  2013-02-20       Impact factor: 0.660

6.  Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases.

Authors:  Florent Duval; Delia Elva Cruz-Vega; Ivonne González-Gamboa; María Teresa González-Garza; Fernando Ponz; Flora Sánchez; Gabriela Alarcón-Galván; Jorge E Moreno-Cuevas
Journal:  Dis Markers       Date:  2016-04-24       Impact factor: 3.434

7.  Normal and Fibrotic Rat Livers Demonstrate Shear Strain Softening and Compression Stiffening: A Model for Soft Tissue Mechanics.

Authors:  Maryna Perepelyuk; LiKang Chin; Xuan Cao; Anne van Oosten; Vivek B Shenoy; Paul A Janmey; Rebecca G Wells
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.